Key Points
- Prenetics Global CFO Brian Rosin purchased 18,000 shares at an average price of $21.19, investing approximately $381,420 and becoming the direct owner of the shares.
- Prenetics shares were trading at $25.78, up 10.9%, near their 12-month high of $26.29. The company recently reported a quarterly loss of $0.53 per share, which beat expectations, while revenue of $46.49 million missed estimates.
- Analyst sentiment is moderately bullish, with four Buy ratings and one Sell rating and a consensus price target of $34.25; institutional investors own 25.01% of the company.
Prenetics Global Limited (NASDAQ:PRE - Get Free Report) CFO Brian Rosin purchased 5,100 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was acquired at an average price of $22.80 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer owned 23,100 shares in the company, valued at approximately $526,680. This trade represents a 28.33% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Prenetics Global Stock Performance
PRE stock opened at $25.78 on Thursday. The company has a fifty day moving average price of $19.24 and a 200-day moving average price of $18.98. The company has a market capitalization of $434.91 million, a P/E ratio of -6.20 and a beta of 0.26. Prenetics Global Limited has a 52-week low of $7.27 and a 52-week high of $26.29.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The company had revenue of $46.49 million for the quarter, compared to analysts' expectations of $49.85 million. As a group, sell-side analysts forecast that Prenetics Global Limited will post -1.86 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Prenetics Global
A number of institutional investors have recently modified their holdings of PRE. 683 Capital Management LLC acquired a new position in Prenetics Global in the fourth quarter valued at $1,181,000. T3 Companies LLC bought a new stake in Prenetics Global during the fourth quarter valued at $170,000. Kingsview Wealth Management LLC acquired a new stake in Prenetics Global during the 4th quarter worth about $172,000. Renaissance Technologies LLC grew its holdings in Prenetics Global by 85.1% during the 1st quarter. Renaissance Technologies LLC now owns 31,322 shares of the company's stock worth $605,000 after acquiring an additional 14,400 shares during the period. Finally, Boothbay Fund Management LLC bought a new position in shares of Prenetics Global in the 4th quarter worth about $241,000. 25.01% of the stock is owned by institutional investors.
Analyst Ratings Changes
PRE has been the topic of a number of analyst reports. Benchmark upped their price target on Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Prenetics Global in a research report on Friday, July 17th. Finally, Wall Street Zen raised Prenetics Global from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.25.
View Our Latest Stock Report on PRE
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
